Maxim Group initiated coverage on Citius Oncology with a new price target
$CTOR
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00
Get the next $CTOR alert in real time by email
Get the next $CTOR alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $CTOR
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/27/2024 | $3.00 | Buy | Maxim Group |
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fiscal First Quarter 2025 Business Highlights and Subsequent Developments Engaged Jefferies as exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value, with multiple active discussi
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fiscal First Quarter 2025 Business Highlights and Subsequent Developments Substantially advanced operational readiness for commercial launch of LYMPHIR in the first half of 2025;Secured a new permanent J-code, J9161, (Injection, denileukin diftitox-cxdl, for intravenous use, 1 microgram) for LYMPHIR™, assigned by the Centers for Medicare & Medicaid Serv
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ (denileukin diftitox-cxdl) has been assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by the Centers for Medicare & Medicaid
Maxim Group initiated coverage on Citius Oncology with a new price target
Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00
SEC Form 4 filed by Director Mayersohn Joel David
4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
SEC Form 4 filed by Director Holuka Eugene Myron
4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
SEC Form 4 filed by Secretary Holubiak Myron Z
4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
Citius Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
SEC Form DEFA14C filed by Citius Oncology Inc.
DEFA14C - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
SEC Form DEF 14C filed by Citius Oncology Inc.
DEF 14C - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma
Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.
SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.
SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
SEC Form SC 13D filed by Citius Oncology Inc.
SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)